WO2025250110 - THE PROLONGED-RELEASE TABLET COMPRISING FAMPRIDINE
National phase entry is expected:
Publication Number
WO/2025/250110
Publication Date
04.12.2025
International Application No.
PCT/TR2025/050556
International Filing Date
26.05.2025
Title **
[English]
THE PROLONGED-RELEASE TABLET COMPRISING FAMPRIDINE
[French]
COMPRIMÉ À LIBÉRATION PROLONGÉE COMPRENANT DE LA FAMPRIDINE
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
SUNEL, Fatih
ATAK, Fadime Bilgehan
IPEK, Celaleddin
PEHLIVAN AKALIN, Nur
ULUSOY BOZYEL, Muge
YENI, Songul
DAGCIOGLU, Erdal
Priority Data
2024/006607
28.05.2024
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2045 | |
| EPO | Filing, Examination, Granting | 9151 | |
| Japan | Filing, Examination, Granting | 2092 | |
| South Korea | Filing, Examination, Granting | 2000 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,028
Contact Us
Abstract[English]
The present invention relates to a prolonged-release tablet comprising fampridine and at least one pharmaceutically acceptable excipient wherein a d (0.9) particle size of fampridine is smaller than 120 µm and at least one cellulosic polymer for prolonged-release.[French]
La présente invention concerne un comprimé à libération prolongée comprenant de la fampridine et au moins un excipient pharmaceutiquement acceptable, une taille de particule d (0,9) de fampridine étant inférieure à 120 µm, et au moins un polymère cellulosique pour une libération prolongée.